Irreversible Electroporation: State of the Art

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 May 25

PMID 27217767

Citations 48

Authors

Peter Gk Wagstaff

Mara Buijs

Willemien van den Bos

Daniel M de Bruin

Patricia J Zondervan

Jean Jmch de la Rosette

M Pilar Laguna Pes

Affiliations

Soon will be listed here.

Abstract

The field of focal ablative therapy for the treatment of cancer is characterized by abundance of thermal ablative techniques that provide a minimally invasive treatment option in selected tumors. However, the unselective destruction inflicted by thermal ablation modalities can result in damage to vital structures in the vicinity of the tumor. Furthermore, the efficacy of thermal ablation intensity can be impaired due to thermal sink caused by large blood vessels in the proximity of the tumor. Irreversible electroporation (IRE) is a novel ablation modality based on the principle of electroporation or electropermeabilization, in which electric pulses are used to create nanoscale defects in the cell membrane. In theory, IRE has the potential of overcoming the aforementioned limitations of thermal ablation techniques. This review provides a description of the principle of IRE, combined with an overview of in vivo research performed to date in the liver, pancreas, kidney, and prostate.

Citing Articles

Image-guided percutaneous ablative treatments for renal cell carcinoma.

Auer T, Uluk Y, Grasso R, Kloeckner R, Gebauer B, Kroencke T Eur Radiol. 2025; .

PMID: 40050457 DOI: 10.1007/s00330-025-11480-w.

3D-cell phantom-experimental setup to assess thermal effects and cell viability of lung tumor cells after electroporation.

Muller N, Gylstorff S, Walles H, Gerlach T, Belker O, Zanasi A Sci Rep. 2024; 14(1):27144.

PMID: 39511318 PMC: 11543935. DOI: 10.1038/s41598-024-78339-w.

Temperature Distribution on Classical Two Needles IRE Setup Versus a Single Needle Prototype.

Jouni A, Baragona M, Pedersoli F, Ritter A Technol Cancer Res Treat. 2024; 23:15330338241288342.

PMID: 39440388 PMC: 11500228. DOI: 10.1177/15330338241288342.

Investigation of High Frequency Irreversible Electroporation for Canine Spontaneous Primary Lung Tumor Ablation.

Hay A, Aycock K, Lorenzo M, David K, Coutermarsh-Ott S, Salameh Z Biomedicines. 2024; 12(9).

PMID: 39335552 PMC: 11428908. DOI: 10.3390/biomedicines12092038.

Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol.

Kalra N, Bhujade H, Baloji A, Khosla D, Samra S, Srinivasan R Cardiovasc Intervent Radiol. 2024; 47(11):1532-1539.

PMID: 39333372 DOI: 10.1007/s00270-024-03856-0.

References

Cho Y, Kim J, Kim M, Rhim H, Han J . Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2008; 49(2):453-9. DOI: 10.1002/hep.22648. View

Niessen C, Igl J, Pregler B, Beyer L, Noeva E, Dollinger M . Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol. 2015; 26(5):694-702. DOI: 10.1016/j.jvir.2015.02.001. View

Narayanan G, Hosein P, Arora G, Barbery K, Froud T, Livingstone A . Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012; 23(12):1613-21. DOI: 10.1016/j.jvir.2012.09.012. View

Pech M, Janitzky A, Wendler J, Strang C, Blaschke S, Dudeck O . Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 2010; 34(1):132-8. DOI: 10.1007/s00270-010-9964-1. View

Olweny E, Kapur P, Tan Y, Park S, Adibi M, Cadeddu J . Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology. 2013; 81(3):679-84. DOI: 10.1016/j.urology.2012.11.026. View

Ficarra V, Novara G, Ahlering T, Costello A, Eastham J, Graefen M . Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012; 62(3):418-30. DOI: 10.1016/j.eururo.2012.05.046. View

Resnick M, Koyama T, Fan K, Albertsen P, Goodman M, Hamilton A . Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368(5):436-45. PMC: 3742365. DOI: 10.1056/NEJMoa1209978. View

Rubinsky B, Onik G, Mikus P . Irreversible electroporation: a new ablation modality--clinical implications. Technol Cancer Res Treat. 2007; 6(1):37-48. DOI: 10.1177/153303460700600106. View

Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R . Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006; 43(5):1101-8. DOI: 10.1002/hep.21164. View

10.

Volpe A, Cadeddu J, Cestari A, Gill I, Jewett M, Joniau S . Contemporary management of small renal masses. Eur Urol. 2011; 60(3):501-15. DOI: 10.1016/j.eururo.2011.05.044. View

11.

Martin 2nd R, McFarland K, Ellis S, Velanovich V . Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012; 215(3):361-9. DOI: 10.1016/j.jamcollsurg.2012.05.021. View

12.

Wagstaff P, de Bruin D, Zondervan P, Savci Heijink C, Engelbrecht M, van Delden O . The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol. BMC Cancer. 2015; 15:165. PMC: 4376341. DOI: 10.1186/s12885-015-1189-x. View

13.

Granot Y, Ivorra A, Maor E, Rubinsky B . In vivo imaging of irreversible electroporation by means of electrical impedance tomography. Phys Med Biol. 2009; 54(16):4927-43. DOI: 10.1088/0031-9155/54/16/006. View

14.

Pandya G, Shelat V . Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future. World J Gastrointest Oncol. 2015; 7(2):6-11. PMC: 4309949. DOI: 10.4251/wjgo.v7.i2.6. View

15.

Davalos R, Bhonsle S, Neal 2nd R . Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy. Prostate. 2015; 75(10):1114-8. PMC: 6680146. DOI: 10.1002/pros.22986. View

16.

van den Bos W, de Bruin D, Jurhill R, Savci-Heijink C, Muller B, Varkarakis I . The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol. 2015; 34(5):657-64. PMC: 4841841. DOI: 10.1007/s00345-015-1661-x. View

17.

van den Bos W, Muller B, Ehdaie B, Scardino P, de la Rosette J . What is still needed to make focal therapy an accepted segment of standard therapy?. Curr Opin Urol. 2014; 24(3):247-55. DOI: 10.1097/MOU.0000000000000043. View

18.

Sharma A, Abtin F, Shepard J . Image-guided ablative therapies for lung cancer. Radiol Clin North Am. 2012; 50(5):975-99. DOI: 10.1016/j.rcl.2012.06.004. View

19.

Wimmer T, Srimathveeravalli G, Gutta N, Ezell P, Monette S, Maybody M . Planning irreversible electroporation in the porcine kidney: are numerical simulations reliable for predicting empiric ablation outcomes?. Cardiovasc Intervent Radiol. 2014; 38(1):182-90. PMC: 5497497. DOI: 10.1007/s00270-014-0905-2. View

20.

Valerio M, Ahmed H, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R . The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2013; 66(4):732-51. PMC: 4179888. DOI: 10.1016/j.eururo.2013.05.048. View